key: cord-0722236-tdll64fw
authors: Gupta, Aayush; Bhoyar, Rahul C.; Mirza, Shahzad; Jolly, Bani; Senthivel, Vigneshwar; Shamnath, Afra; Divakar, Mohit Kumar; Imran, Mohamed; Gupta, Vishu; Agrawal, Srashti Jyoti; Mukhida, Sahjid; Sivasubbu, Sridhar; Scaria, Vinod
title: SARS-CoV-2 vaccine breakthrough infection following a previous infection in a healthcare worker
date: 2021-10-19
journal: J Infect
DOI: 10.1016/j.jinf.2021.10.008
sha: 2b46c4427e2d30e2c37afb846cc1d882bfd88cb5
doc_id: 722236
cord_uid: tdll64fw

nan

Subsequently, he developed fever for 2 days, breathlessness which lasted for seven days along with cough, bodyache and sore throat for ten days. On the seventh day of illness the patient suffered a brief drop in the oxygen saturation (SpO2) to 94% which recovered spontaneously on the next day. High-resolution Computed Tomography (HR-CT) revealed no abnormality and the patient tested negative for SARS-COV-2 on reverse transcription-PCR (RT-PCR). Antibody titres two weeks after testing negative on RT-PCR, revealed a moderate level of antibodies (Elecsys Anti SARS-CoV-2, Roche Diagnostics) to spike protein (12). The patient then proceeded to take the first dose of Covishield/ChAdOx1 vaccine and subsequently the second dose four weeks later. He suffered mild post-vaccine effects including body aches and injection site pain lasting two days after both doses. A month after receiving the second dose, the patient again developed fever and tested positive on RT-PCR (C T of 13) for SARS-CoV-2.

In the second episode of the infection, the patient had fever for four days, and cough, bodyache, headache, sore throat, loss of smell and taste for twelve days. The SpO2 level was around 94-95%, and the patient had mild difficulty in breathing throughout the symptomatic period. His HR-CT was normal and he had no evidence of primary or secondary immunodeficiencies. The clinical course and timelines are summarised in Figure 1A and the clinical parameters are summarised in Table 1 . 

Genomic survey of SARS-CoV-2 vaccine breakthrough infections in healthcare workers from Kerala

COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing

Vaccine Breakthrough Infections with SARS-CoV-2 Variants. Reply

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next-generation sequencing